Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 6:00 AM ET

Date/Time Source News Release
11/07/2023 09:15 AM EST GlobeNewswire Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
11/02/2023 09:15 AM EDT GlobeNewswire Scopus BioPharma's Subsidiary - Duet BioTherapeutics - to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
11/10/2022 09:15 AM EST GlobeNewswire Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
10/18/2022 09:25 AM EDT GlobeNewswire Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
05/05/2022 08:30 AM EDT GlobeNewswire Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
03/22/2022 08:30 PM EDT GlobeNewswire Scopus BioPharma's Subsidiary - Duet BioTherapeutics - to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
01/10/2022 08:30 AM EST GlobeNewswire Scopus BioPharma Provides Update Following Annual Meeting of Stockholders
01/06/2022 07:00 AM EST PR Newswire DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS
12/17/2021 08:00 AM EST GlobeNewswire Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company
12/07/2021 08:30 AM EST GlobeNewswire Scopus BioPharma Sends Letter Urging Stockholders to Vote "FOR ALL" of the Company's Director Nominees on the WHITE Proxy Card
Page